Electronic Supplementary Material (ESI) for Catalysis Science & Technology. This journal is © The Royal Society of Chemistry 2015

Supporting Information

for

# Selective NaOH-catalysed hydration of aromatic nitriles to amides

Thibault E. Schmid, Alberto Gómez-Herrera, Olivier Songis, Deborah Sneddon, Antoine Révolte, Fady Nahra and Catherine S. J. Cazin\*

EaStCHEM School of Chemistry, University of St Andrews, St Andrews KY16 9ST, U.K. <a href="mailto:cc111@st-andrews.ac.uk">cc111@st-andrews.ac.uk</a>

# **Table of Contents**

General informationS	S3
General procedure for the optimization of reaction conditions (Table 1)	S3
General procedure for nitriles hydration (Scheme 1)	S3
In situ IR monitoring	S4
Determination of k <sub>1</sub> (Figure 1)	S6
NMR of products	S8
Benzamide	S8
o-Bromobenzamide	S9
o-Nitrobenzamide	S10
Anthranilamide	S11
<i>m</i> -Toluamide	S12
m-(Trifluoromethyl)benzamide	S13
m-Bromobenzamide <sup>1</sup>	S14
m-Acetylbenzamide	S15
<i>m</i> -Nitrobenzamide	S16
<i>p</i> -(Trifluoromethyl)benzamide	S17
<i>p</i> -Nitrobenzamide	S18
<i>p</i> -Toluamide	S19
p-Acetylbenzamide	S20
<i>p</i> -Fluorobenzamide	S21
<i>p</i> -Methoxybenzamide	S22
<i>p</i> -Chlorobenzamide	S23
Isophthalamide	S24
Terephthalamide	S25
2-Furamide	S26
Isonicotinamide	S27
1 <i>H</i> -Pyrrole-2-carboxamide	S28
References	S29

#### **General information**

All reactions were carried out in air. Flash column chromatography purifications were performed on silica gel 60 (230-400 mesh). <sup>1</sup>H and <sup>13</sup>C-{<sup>1</sup>H} Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker AC300 or on a Bruker Advance 400 Ultrashield spectrometer at 298K, gas chromatography (GC) analyses were performed on an Agilent 7890A apparatus equipped with a flame ionisation detector and a (5%-Phenyl)-methylpolysiloxane column. IR measurements were performed on a ReactIR A15 system (Mettler Toledo Autochem) with a DiComp AgX FiberConduit probe (9.5 mm). All glassware was dried in an oven at 80 °C prior to use. All reagents (unless otherwise noted) were purchased and used without further purification. Solvents were purchased and used as received.

# General procedure for the optimization of reaction conditions (Table 1)

A screwcap vial fitted with a septum and equipped with a stirring bar was charged with benzonitrile (0.1 mL, 1 mmol), the required amount of base, and the solvent (0.5 mL). The reaction mixture was stirred at 90 °C or 110 °C (external temperature) for 17 hours. A saturated solution of sodium chloride (5 mL) and EtOAc (5 mL) were added to the reaction mixture. The two layers were separated and the aqueous phase was extracted with EtOAc (5x5 mL). The aqueous phase was acidified by addition of an HCl aqueous solution (1 M, 10 mL), and the resulting suspension was extracted with EtOAc (5x5 mL). All organic extracts were combined, dried over MgSO<sub>4</sub>, filtered, and concentrated under vacuum. The resulting mixture was diluted in acetone (10 mL), and a standard solution of mesitylene (0.5 M in acetone, 1 mL) was added for GC analysis.

# General procedure for nitriles hydration (Scheme 1)

A screwcap-vial fitted with a septum and equipped with a stirring bar was charged with the nitrile (1 mmol), NaOH (0.1 mmol) and the solvent (0.5 mL). The reaction mixture was stirred at 90 °C (external temperature) for 17 hours.

#### Workup A

A saturated solution of sodium chloride (5 mL) and EtOAc (5 mL) were added to the reaction mixture. The two layers were separated and the aqueous phase was extracted with EtOAc (5x5 mL). The organic extracts were combined, dried over MgSO<sub>4</sub>, filtered and concentrated

under vacuum. If necessary, the resulting solid was purified by flash chromatography using a gradient of pentane/EtOAc (7:3 to 0:1).


#### Workup B


The reaction mixture was cooled down to 4 °C for 24 h. The resulting precipitate was collected by filtration and washed with water (4 mL) and acetone (4 mL), and further dried at 80 °C for 5 h.


# In situ IR monitoring

Sodium benzoate and sodium acetate were freshly prepared by boiling benzoic acid or glacial acetic acid with an aqueous NaOH solution until dryness. All other substrates were commercially available. 2 M solutions (15 mL, EtOH/H<sub>2</sub>O, 7:3) were prepared for the IR spectra library. All spectra were collected at 80 °C in air.

A 25 mL two-necked round-bottomed flask was charged with the substrate (24 mmol) and  $EtOH/H_2O$  (7:3 v/v, 12 mL). The reaction mixture was warmed to 90 °C (external temperature, internal temperature: 83-84 °C), and IR monitoring was started. The catalyst, NaOH (10 mol%) was then added, and the reaction evolution was monitored.







# **Determination of k**<sub>1</sub> (**Figure 1**)


The validity of the Beer- Lambert law was considered for the presented reactive system.

Differential rate equation:  $v = k_1[PhCN][OH^-]$ 


Catalytic base  $\rightarrow$  v =  $k'_1[PhCN]$ 

Integrated rate equation:  $Ln [PhCN] = Ln [PhCN]_0 - k'_1t$ 

#### COMPLETE EXPERIMENTAL PLOT



#### REFINED EXPERIMENTAL PLOT<sup>a</sup>



<sup>&</sup>lt;sup>a</sup>Representation and calculation data refined to 3 half lives

$$Ln [PhCN] = Ln [PhCN]_0 - k'_1t$$

1. 
$$k'_1 = 3 \cdot 10^{-4} \text{ s}^{-1}$$

**2.** 
$$t_{1/2} = (\text{Ln 2})/\text{k'}_1 \approx 39 \text{ min}$$

**3.** Ln [PhCN]
$$_0$$
 = -1.2777 ; [PhCN] $_0$  = 0.28 M ; [OH $^-$ ] $_0$  = [OH $^-$ ] = 0.1 x [PhCN] $_0$  = 0.028 M

**4.** 
$$k'_1 = k_1[OH^-]$$
  $k_1 = 1.1 \cdot 10^{-2} M^{-1} \cdot s^{-1}$ 


# **NMR** of products

# Benzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (99 mg, 82%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.36 (br. s, 1H, NH), 7.42-7.47 (m, 2H, CH<sub>Ar</sub>), 7.50-7.54 (m, 1H, CH<sub>Ar</sub>), 7.85-7.89 (m, 2H, CH<sub>Ar</sub>), 7.96 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 127.4 (s, CH<sub>Ar</sub>), 128.2 (s, CH<sub>Ar</sub>), 131.2 (s, CH<sub>Ar</sub>), 134.3 (s, C<sub>Ar</sub>), 167.9 (s, CONH<sub>2</sub>).





# o-Bromobenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (174 mg, 87%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.30-7.35 (m, 1H, CH<sub>Ar</sub>), 7.39-7.41 (m, 2H, CH<sub>Ar</sub>), 7.56 (br. s, 1H, NH), 7.62-7.64 (m, 1H, CH<sub>Ar</sub>), 7.85 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 118.6 (s, C<sub>Ar</sub>), 127.5 (s, CH<sub>Ar</sub>), 128.5 (s, CH<sub>Ar</sub>), 130.6 (s, CH<sub>Ar</sub>), 132.7 (s, CH<sub>Ar</sub>), 139.4 (s, C<sub>Ar</sub>), 169.0 (s, CONH<sub>2</sub>).






#### o-Nitrobenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A followed by flash chromatography) as a colourless solid (113 mg, 68%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.61-7.72 (m, 3H, C $H_{Ar}$  + NH), 7.76 (td,  $^3J_{H-H}$  = 8.0 Hz,  $^4J_{H-H}$  = 1.2 Hz, 1H, C $H_{Ar}$ ), 7.99 (dd,  $^3J_{H-H}$  = 8.0 Hz,  $^4J_{H-H}$  = 1.2 Hz, 1H, C $H_{Ar}$ ), 8.14 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 123.9 (s, CH<sub>Ar</sub>), 128.8 (s, CH<sub>Ar</sub>), 130.6 (s, CH<sub>Ar</sub>), 132.6 (s, C<sub>Ar</sub>), 133.3 (s, CH<sub>Ar</sub>), 147.2 (s, C<sub>Ar</sub>), 167.1 (s, CONH<sub>2</sub>).




# **Anthranilamide**<sup>2</sup>

The general procedure afforded the title compound by using (workup A followed by flash chromatography) as a colourless solid (86 mg, 63%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 6.44-6.49 (m, 1H, CH<sub>Ar</sub>), 6.55 (s, 2H, NH<sub>2</sub>), 6.67 (dd,  ${}^3J_{\text{H-H}}$  = 8.0 Hz,  ${}^4J_{\text{H-H}}$  = 1.2 Hz, 1H, CH<sub>Ar</sub>), 7.05 (br. s, 1H, NH), 7.09-7.15 (m, 1H, CH<sub>Ar</sub>), 7.52 (dd,  ${}^3J_{\text{H-H}}$  = 8.0 Hz,  ${}^4J_{\text{H-H}}$  = 1.2 Hz, 1H, CH<sub>Ar</sub>), 7.71 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 113.7 (s, C<sub>Ar</sub>), 114.4 (s, CH<sub>Ar</sub>), 116.4 (s, CH<sub>Ar</sub>), 128.8 (s, CH<sub>Ar</sub>), 131.9 (s, CH<sub>Ar</sub>), 150.2 (s, C<sub>Ar</sub>), 171.3 (s, CONH<sub>2</sub>).





#### m-Toluamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (112 mg, 83%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 2.34 (s, 3H, CH<sub>3</sub>), 7.32 (d,  $^3J_{\text{H-H}}$  = 4.4 Hz, 3H, CH<sub>Ar</sub>), 7.64-7.69 (m, 1H, CH<sub>Ar</sub>), 7.70 (s, 1H, NH), 7.92 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 21.0 (CH<sub>3</sub>), 124.6 (s, CH<sub>Ar</sub>), 128.1 (s, CH<sub>Ar</sub>), 131.8 (s, CH<sub>Ar</sub>), 134.3 (s, C<sub>Ar</sub>), 137.4 (s, C<sub>Ar</sub>), 168.0 (s, CONH<sub>2</sub>).







# *m*-(Trifluoromethyl)benzamide<sup>3</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (180 mg, 95%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.63 (br. s, 1H, NH), 7.71 (dd,  ${}^3J_{\text{H-H}}$  = 8.8 Hz,  ${}^3J_{\text{H-H}}$  = 7.8 Hz, 1H, CH<sub>Ar</sub>), 7.89 (d,  ${}^3J_{\text{H-H}}$  =8.0 Hz, 1H, CH<sub>Ar</sub>), 8.18 (d,  ${}^3J_{\text{H-H}}$  =8.0 Hz, 1H, CH<sub>Ar</sub>), 8.21 (s, 1H, CH<sub>Ar</sub>), 8.24 (s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 124.0 (q,  ${}^{1}J_{\text{C-F}}$  = 272.5 Hz, CF<sub>3</sub>), 124.1 (q,  ${}^{3}J_{\text{C-F}}$  = 3.8 Hz, CH<sub>Ar</sub>), 127.9 (q,  ${}^{3}J_{\text{C-F}}$  = 3.8 Hz, CH<sub>Ar</sub>), 129.1 (q,  ${}^{2}J_{\text{C-F}}$  = 32.0 Hz, C<sub>Ar</sub>), 129.6 (s, CH<sub>Ar</sub>), 131.5 (s, CH<sub>Ar</sub>), 135.2 (s, C<sub>Ar</sub>), 166.4 (s, CONH<sub>2</sub>).







#### m-Bromobenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (178 mg, 89%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.43 (t,  $^3J_{\text{H-H}}$  = 8.0 Hz, 1H, CH<sub>Ar</sub>), 7.52 (br. s, 1H, NH), 7.71-7.74 (m, 1H, CH<sub>Ar</sub>), 7.85-7.88 (m, 1H, CH<sub>Ar</sub>), 8.04 (d,  $^4J_{\text{H-H}}$  = 1.2 Hz, 1H, CH<sub>Ar</sub>), 8.08 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 121.6 (s, C<sub>Ar</sub>), 126.6 (s, CH<sub>Ar</sub>), 130.2 (s, CH<sub>Ar</sub>), 130.5 (s, CH<sub>Ar</sub>), 134.0 (s, CH<sub>Ar</sub>), 136.5 (s, C<sub>Ar</sub>), 166.3 (s, CONH<sub>2</sub>).







# m-Acetylbenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A followed by flash chromatography) as a colourless solid (142 mg, 87%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 2.63 (s, 3H, CH<sub>3</sub>), 7.53 (br. s, 1H, NH), 7.61 (t,  ${}^3J_{\text{H-H}}$  = 8.0 Hz, 1H, CH<sub>Ar</sub>), 8.08-8.13 (m, 2H, CH<sub>Ar</sub>), 8.18 (br. s, 1H, NH), 8.43 (m, 1H, CH<sub>Ar</sub>).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 26.9 s, CH<sub>3</sub>), 127.2 (s, CH<sub>Ar</sub>), 128.8 (s, CH<sub>Ar</sub>), 130.7 (s, CH<sub>Ar</sub>), 132.0 (s, CH<sub>Ar</sub>), 134.7 (s, C<sub>Ar</sub>), 136.8 (s, C<sub>Ar</sub>), 167.1 (s, CONH<sub>2</sub>), 197.7 (s, COCH<sub>3</sub>).






#### m-Nitrobenzamide<sup>4</sup>

The general procedure afforded the title compound (workup A) as a pale yellow solid (140 mg, 84%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.72 (br. s, 1H, NH), 7.77 (t,  ${}^3J_{\text{H-H}}$  = 8.0 Hz, 1H, CH<sub>Ar</sub>), 8.29-8.32 (m, 1H, CH<sub>Ar</sub>), 8.34 (br. s, 1H, NH), 8.36-8.40 (m, 1H, CH<sub>Ar</sub>), 8.69 (t,  ${}^4J_{\text{H-H}}$  = 1.2 Hz, 1H, CH<sub>Ar</sub>).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, (DMSO- $d_6$ ): δ (ppm) = 122.2 (s, CH<sub>Ar</sub>), 125.9 (s, CH<sub>Ar</sub>), 130.1 (s, CH<sub>Ar</sub>), 133.8 (s, CH<sub>Ar</sub>), 135.8 (s, C<sub>Ar</sub>), 147.8 (s, C<sub>Ar</sub>), 165.7 (s, CONH<sub>2</sub>).







# p-(Trifluoromethyl)benzamide<sup>3</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (170 mg, 90%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.63 (br. s, 1H, NH), 7.83 (d,  $^3J_{\text{H-H}}$  = 8.0 Hz, 2H, CH<sub>Ar</sub>), 8.06 (d,  $^3J_{\text{H-H}}$  = 8.0 Hz, 2H, CH<sub>Ar</sub>), 8.20 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 124.0 (q,  ${}^{1}J_{\text{C-F}}$  = 271.4 Hz, CF<sub>3</sub>), 125.3 (q,  ${}^{3}J_{\text{C-F}}$  = 3.6 Hz, CH<sub>Ar</sub>), 128.4 (s, CH<sub>Ar</sub>), 131.2 (s,  ${}^{2}J_{\text{C-F}}$  = 31.9 Hz, C<sub>Ar</sub>), 138.1 (s, C<sub>Ar</sub>), 166.8 (s, CONH<sub>2</sub>).







# p-Nitrobenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (150 mg, 90%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.73 (br. s, 1H, NH), 8.08-8.11 (m, 2H, CH<sub>Ar</sub>), 8.26-8.32 (m, 3H, NH + C $H_{Ar}$ ).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 123.5 (s, CH<sub>Ar</sub>), 128.9 (s, CH<sub>Ar</sub>), 140.0 (s, C<sub>Ar</sub>), 149.1 (s, C<sub>Ar</sub>), 166.2 (s, CONH<sub>2</sub>).







# p-Toluamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (114 mg, 84%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 2.34 (s, 3H, CH<sub>3</sub>), 7.22-7.29 (m, 3H, NH + CH<sub>Ar</sub>), 7.77 (d,  $^3J_{\text{H-H}}$  = 8.0 Hz, 2H, CH<sub>Ar</sub>), 7.88 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 21.0 (s, CH<sub>3</sub>), 127.5 (s, CH<sub>Ar</sub>), 128.7 (s, CH<sub>Ar</sub>), 131.5 (s, C<sub>Ar</sub>), 141.1 (s, C<sub>Ar</sub>), 167.8 (s, CONH<sub>2</sub>).






# p-Acetylbenzamide<sup>3</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (137 mg, 84%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 2.61 (s, 3H, CH<sub>3</sub>), 7.57 (br. s, 1H, NH), 7.97-8.02 (m, 4H, CH<sub>Ar</sub>), 8.15 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 27.0 (s, CH<sub>3</sub>), 127.8 (s, CH<sub>Ar</sub>), 128.1 (s, CH<sub>Ar</sub>), 138.1 (s, C<sub>Ar</sub>), 138.7 (s, C<sub>Ar</sub>), 167.1 (s, CONH<sub>2</sub>), 197.7 (s, COCH<sub>3</sub>).




# p-Fluorobenzamide<sup>5</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (134 mg, 96%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.25-7.30 (m, 2H, CH<sub>Ar</sub>), 7.39 (br. s, 1H, NH), 7.92-7.96 (m, 2H, CH<sub>Ar</sub>), 7.99 (br. s, 1H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 115.1 (d,  ${}^2J_{\text{C-F}}$  = 20.7 Hz, CH<sub>Ar</sub>), 130.1 (d,  ${}^3J_{\text{C-F}}$  = 8.1 Hz, CH<sub>Ar</sub>), 130.7 (d,  ${}^4J_{\text{C-F}}$  = 2.7 Hz, C<sub>Ar</sub>), 163.9 (d,  ${}^1J_{\text{C-F}}$  = 248.2 Hz, C<sub>Ar</sub>), 166.8 (s, CONH<sub>2</sub>).







# p-Methoxybenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (130 mg, 86%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 3.80 (s, 3H, OC $H_3$ ), 6.96-6.98 (m, 2H, CH<sub>Ar</sub>), 7.17 (br. s, 1H, NH), 7.82-7.86 (m, 3H, NH + C $H_{Ar}$ ).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 55.3 (s, OCH<sub>3</sub>), 113.4 (s, CH<sub>Ar</sub>), 126.5 (s, C<sub>Ar</sub>), 129.4 (s, CH<sub>Ar</sub>), 161.6 (s, C<sub>Ar</sub>), 167.4 (s, CONH<sub>2</sub>).







# p-Chlorobenzamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (140 mg, 90 %).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.46 (br. s, 1H, NH), 7.51-7.54 (m, 2H, CH<sub>Ar</sub>), 7.87-7.89 (m, 2H, CH<sub>Ar</sub>), 8.04 (br. s, 2H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 128.3 (s, CH<sub>Ar</sub>), 129.4 (s, CH<sub>Ar</sub>), 133.0 (s, C<sub>Ar</sub>), 136.1 (s, CH<sub>Ar</sub>), 166.8 (s, CONH<sub>2</sub>).






# Isophthalamide<sup>1</sup>

The general procedure afforded the title compound (workup B) as a colourless solid (99 mg, 60%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.46 (br. s, 2H, N $H_2$ ), 7.53 (t,  $^3J_{\text{H-H}}$  = 8.0 Hz, 1H, C $H_{\text{Ar}}$ ), 7.99 (dd,  $^3J_{\text{H-H}}$  = 8.0 Hz,  $^4J_{\text{H-H}}$  = 1.2 Hz, 2H, C $H_{\text{Ar}}$ ), 8.03 (br. s, 2H, NH), 8.36 (t,  $^4J_{\text{H-H}}$  = 1.2 Hz, 1H, C $H_{\text{Ar}}$ ).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 126.8 (s,  $CH_{Ar}$ ), 128.3 (s,  $CH_{Ar}$ ), 130.1 (s,  $CH_{Ar}$ ), 134.5 (s,  $C_{Ar}$ ), 167.6 (s,  $CONH_2$ ).







# Terephthalamide<sup>1</sup>

The general procedure afforded the title compound (workup B) as a colourless solid (135 mg, 82%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.49 (br. s, 2H, NH), 7.92 (s, 4H, CH<sub>Ar</sub>), 8.07 (br. s, 2H, NH).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 127.4 (s, CH<sub>Ar</sub>), 136.6 (s, C<sub>Ar</sub>), 167.3 (s, CONH<sub>2</sub>).







# 2-Furamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (98 mg, 88%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 6.59-6.60 (m, 1H, CH<sub>Ar</sub>), 7.09 (d,  $^3J_{\text{H-H}}$  = 3.3 Hz, 1H, CH<sub>Ar</sub>), 7.36 (br. s, 1H, NH), 7.75 (br. s, 1H, NH), 7.80 (m, 1H, CH<sub>Ar</sub>).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 111.8 (s, CH<sub>Ar</sub>), 113.6 (s, CH<sub>Ar</sub>), 145.0 (s, CH<sub>Ar</sub>), 148.1 (s, C<sub>Ar</sub>), 159.4 (s, CONH<sub>2</sub>).







# **Isonicotinamide**<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (88 mg, 72%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 7.72 (br. s, 1H, NH), 7.75-7.77 (m, 2H, CH<sub>Ar</sub>), 8.24 (br. s, 1H, NH), 8.70-8.72 (m, 2H, CH<sub>Ar</sub>).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 121.4 (s, CH<sub>Ar</sub>), 141.3 (s, C<sub>Ar</sub>), 150.2 (s, CH<sub>Ar</sub>), 166.3 (s, CONH<sub>2</sub>).







# 1H-Pyrrole-2-carboxamide<sup>1</sup>

The general procedure afforded the title compound (workup A) as a colourless solid (96 mg, 87%).

<sup>1</sup>H NMR (400 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 6.06 (m, 1H, CH<sub>Ar</sub>), 6.76 (m, 1H, CH<sub>Ar</sub>), 6.83 (m, 1H, CH<sub>Ar</sub>), 6.92 (br. s, 1H, NH), 7.47 (br. s, 1H, NH), 11.39 (s, 1H, NH<sub>Ar</sub>).

<sup>13</sup>C-{<sup>1</sup>H} NMR (100.62 MHz, 298K, DMSO- $d_6$ ): δ (ppm) = 108.6 (s, CH<sub>Ar</sub>), 110.7 (s, CH<sub>Ar</sub>), 121.4 (s, CH<sub>Ar</sub>), 126.3 (s, C<sub>Ar</sub>), 162.3 (s, CONH<sub>2</sub>).





# References

- 1. R. S. Ramon, N. Marion and S. P. Nolan, Chem. Eur. J. 2009, 15, 8695.
- 2. A. D.Roy,; A.Subramanian,; R.Roy, J. Org. Chem. 2006, 71, 382.
- 3. A. Schnyder, M. Beller, G. Mehltretter, T. Nsenda, M. Studer and A. F. Indolese, *J. Org. Chem.* 2001, **66**, 4311.
- 4. M. A. Ali and T. Punniyamurthya, Adv. Synth. Catal. 2010, 352, 288.
- 5. R. S. Ramon, J. Bosson, S. Diez-Gonzalez, N. Marion and S. P. Nolan, *J. Org. Chem.* 2010, **75**, 1197.
- 6. W.-C. Lee and B. J. Frost, Green Chem. 2012, 14, 62.